Incyte Corporation (NASDAQ: INCY) reiterated to Overweight with price target $125 by Barclays
Barclays reiterated Incyte Corporation (NASDAQ: INCY) to Overweight with price target $125. Previously Barclays reiterated Incyte Corporation (NASDAQ: INCY) to Overweight with price target
$75 on 02/13/2014, when the stock price was $66.00. Since then, Incyte Corporation's stock price has gained 64% as of 08/13/2015's recent price of $108.44. If you would have followed the previous Barclays's recommendation on INCY, you would have gained 64% of your investment in 546 days.
(Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs in oncology, inflammation and diabetes. Incyte?s pipeline includes compounds in various stages of development in the areas of oncology, inflammation, diabetes and human immunodeficiency virus (HIV).